Cooley advised publicly traded clinical-stage immuno-oncology company Forty Seven on its agreement to sell to Gilead for $4.9 billion in all cash. Partners Jamie Leigh, Ben Beerle, Eric Jensen and John McKenna led the Cooley team advising Forty Seven on the transaction, which is expected close in Q2.